
MDT · NYSE
Medtronic is a publicly traded company identified in the supplied materials by its ticker, MDT, but those materials do not specify its products, operating segments, customer groups, geographic footprint, or revenue contribution by business. The available financial figures show a company that generated $36.4 billion of revenue and $4.8 billion of net income in FY2026, versus $33.5 billion of revenue and $4.7 billion of net income in FY2025. Thus, the evidence supports its current financial scale and year-over-year results, but not a reliable description of how sales are divided or how the company makes money by segment.
Medtronic shares fell $0.68, or 0.78%, from $86.88 to $86.20 over the reported week. Trading reversed within the period: the stock rose to $87.54 on July 29, then gave back that gain over the next two sessions, closing at $85.39 on July 31. It rebounded 1.51% to $86.68 on Monday, August 3, according to Zacks, before slipping 0.55% on Tuesday. The supplied evidence identifies no company-specific announcement, earnings release, guidance change, or contract behind the move. The stock therefore moved without an established company catalyst; the evidence also does not provide a broader market explanation.
Medtronic (NYSE: MDT) grants 49,167 options and PSUs to EVP